Google
English
French
German
Italian
Japanese
Portuguese
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Ionis announces FDA acceptance of New Drug Application for eplontersen for the treatment of hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN)
CARLSBAD, Calif., March 7, 2023 /PRNewswire/ — Ionis Pharmaceuticals (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a New Drug Application (NDA) for eplontersen, an investigational antisense medicine for the treatment of people living with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN). The application has been given a Prescription Drug User Fee Act (PDUFA) action date of Dec. 22, 2023.
myBinderRelated Content
-
ISA 2020 | Burning Questions: ASCT in AL Amyloidosishttps://www.youtube.com/watch?v=KmcLvnXC...
-
Webinar Presentation by Chafic Karam on Peripheral and Autonomic Neuropathyhttps://www.youtube.com/watch?v=9PsSST2g...
-
Ionis Clinical Trial Update – ASG Webinar 6/11https://www.youtube.com/watch?v=K2TmwAfu...
-
Financial Assistance Update by Paula Schmitt – ASG Webinar 7.15.23 – 5/7https://www.youtube.com/watch?v=UcxmPgZ7...
-
FPN Webinar: Hereditary Neuropathy and Genetic TestingThe Foundation for Peripheral Neuropathy...
-
Stem Cell Transplant or Dara-CyBorD – ASG Webinar 12/13https://www.youtube.com/watch?v=4gUXPbOk...
-
Cardiac Amyloidosis: Where are We Today?Systemic amyloidosis is generally consid...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
